MASHINIi

Agios Pharmaceuticals, Inc..

AGIO.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing novel medicines for the treatment of cancer and rare genetic diseases. The company's research and development efforts are centered on cellular metabolism and related pathways. Agios develops targeted the...Show More

Ethical Profile

Mixed.

Agios Pharmaceuticals develops rare disease therapies; its lead product PYRUKYND includes patient support. Reports suggest a strong safety record, though PYRUKYND carries potential serious side effects. A fair 20:1 CEO-to-median pay ratio exists, but critics cite employee concerns on management and diversity. Agios targets CO2 reduction and holds ISO 14001:2015, but environmental efforts lag benchmarks. While adhering to a Code of Conduct, it allegedly received occasional warning letters, and transparency is limited by a lack of quantitative data.

Value Scores

Better Health for All-20
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect30
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business-40
-100100
Kind to Animals0
-100100
No War, No Weapons0
-100100
Planet-Friendly Business-20
-100100
Respect for Cultures & Communities-20
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products-40
-100100

Better Health for All

-20

Agios Pharmaceuticals focuses on developing therapies for rare, life-threatening genetically defined diseases, including PK deficiency, alpha- and beta-thalassemia, sickle cell disease, MDS-associated anemia, and phenylketonuria (PKU).

1
Their first approved therapy is for PK deficiency.
2
As of December 31, 2021, the company reported no FDA recalls, no fatalities related to its products, and zero FDA enforcement actions for GMP violations.
3
However, their product PYRUKYND® has potential serious side effects, including acute hemolysis and liver injury.
4
The company offers patient assistance programs like a $0 copay program for eligible U.S. patients with commercial insurance and a Patient Assistance Program for uninsured/underinsured patients, but specific cost-plus pricing or affordability metrics are not provided.
5
Agios supports patient communities through advocacy groups, a global patient registry, and a no-cost next-generation sequencing testing program.
6
The company invested $298.5 million in R&D in 2021 and $1.4 billion over five years.
7
Agios established a clinical trial task force to support patient participation during the COVID-19 pandemic, implementing at-home study visits and telemedicine.
8
The company is committed to protecting patient data and complying with privacy laws, and shares clinical trial data responsibly and transparently with qualified researchers.
9

Fair Money & Economic Opportunity

0

No evidence available to assess Agios Pharmaceuticals, Inc. on Fair Money & Economic Opportunity.

Fair Pay & Worker Respect

30

The company's CEO-to-median employee pay ratio for 2024 was 20:1, with CEO Brian Goff's total compensation at $6,776,359 and the median employee pay at $331,591.

1
Employee reviews on Glassdoor indicate an overall rating of 4.0 out of 5 stars (equivalent to 80/100) from 103 reviews.
2
Additionally, 88% of employees approve of the CEO, and 74% would recommend working at the company.
3
Compensation and benefits received a rating of 4.3 out of 5 stars, though this rating decreased by 1% over the last 12 months.
4

Fair Trade & Ethical Sourcing

0

No specific, quantitative evidence was found in the provided articles for any of the KPIs related to Fair Trade & Ethical Sourcing. Information regarding fair-trade certifications, supplier audit frequencies, incidents of forced or child labor, supply chain traceability, remediation speed, ethical clause coverage in supplier contracts, materials risk, or supplier diversity spend was either absent, too general, or not quantitative enough to map to the rubric's specific thresholds.

1

Honest & Fair Business

-40

Agios Pharmaceuticals has a Code of Business Conduct and Ethics and a compliance program based on OIG Compliance Program Guidance and the PhRMA Code.

1
A confidential and anonymous compliance helpline is available 24/7, and retaliation against good-faith reporters is strictly prohibited.
2
All new employees receive basic compliance training during onboarding, with additional annual healthcare compliance training.
3
However, the effectiveness of this program is not publicly measured. The company states it has a majority independent board.
4
Its anti-corruption policy is consistent with the PhRMA Code, but the articles do not provide details on the frequency or effectiveness metrics of its training.
5

Kind to Animals

0

No specific, concrete data points or facts were found in the provided articles regarding Agios Pharmaceuticals, Inc.'s performance related to animal welfare, animal testing, ethical sourcing, or conservation initiatives. All articles explicitly state that they contain no relevant data for AGIO.US or the 'Kind to Animals' value.

1
Therefore, no KPIs can be scored.

No War, No Weapons

0

No evidence available to assess Agios Pharmaceuticals, Inc. on No War, No Weapons.

Planet-Friendly Business

-20

Agios Pharmaceuticals reported total Scope 1, 2, and 3 greenhouse gas emissions of 8,234 metric tons CO2 equivalent in 2022.

1
In the same year, 22% of the company's operational energy consumption was sourced from renewables.
2
The company has an ISO 14001:2015 certification and recorded zero environmental compliance violations in 2022.
3
Agios has set a net-zero target year of 2025, with a target reduction of 25%.
4

Respect for Cultures & Communities

-20

Agios Pharmaceuticals has established 9 distinct formal partnerships with local community groups and advocacy organizations, including the Thalassemia International Federation, Hemolytic Anemia Patient Coalition, Happy Hope Foundation, Kids in Tech, Coalition for a Better Acre, Life Science Cares, Greater Boston Food Bank, the Frank and Rosemary Iovieno Caring for Children Foundation, and the International PK deficiency patient advocacy advisory council.

1
The company has not reported any cultural appropriation incidents.
2
Agios provided more than $770,000 in unrestricted medical education grants and $20,000 in corporate giving donations to Life Science Cares.
3
It also raised funds for the Sickle Cell Community Consortium (SCCC) COVID-19 relief fund and sponsored MassBio’s Rare Disease Day and DISORDER: The Rare Disease Film Festival with $15,000.
4
Unconscious bias training is provided to employees, and a Martin Luther King Day BINGO card was created to encourage employees to educate themselves on issues of race, poverty, and inequality.
5

Safe & Smart Tech

0

No evidence available to assess Agios Pharmaceuticals, Inc. on Safe & Smart Tech.

Zero Waste & Sustainable Products

-40

Agios Pharmaceuticals has implemented several waste reduction initiatives, including providing compostable cafeteria products, single-stream recycling, water bottle refill stations, and pipette tip recycling.

1
The company also reports reduced plastic waste.
2
For hazardous waste, Agios maintains certifications such as CIH, ASP, HAZWOPER (40-hour), and RCRA/DOT, indicating adherence to applicable laws and regulations related to health and safety.
3

Own Agios Pharmaceuticals, Inc.?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.